Gemcitabine, which has activity in many solid tumours, has been combined with the monoclonal anti-VEGF antibody bevacizumab for the treatment of hepatocellular carcinoma or advanced pancreatic cancer (Kindler et al, 2005; Zhu et al, 2006). Here, VEGFA is linked to familial pancreatic carcinoma.